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1. Introduction
A growing number of clinical studies suggest that antipsychotic 
action starts early and increases in magnitude with repeated 
treatment (Agid et al., 2003, 2006; Emsley et al., 2006; Glick et al., 
2006; Kapur et al., 2005; Leucht et al., 2005; Raedler et al., 2007). 
This observation is strongly supported by the finding that im-
provement of psychotic symptoms occurs within the first week 
of treatment and shows a progressive increase over the subse-
quent weeks. For example, Agid et al. (2003) examined 42 dou-
ble-blind, comparator-controlled studies (> 7000 patients) using 
a meta-analysis technique. They found that psychotic symp-
toms improved within the first week of treatment and showed 
a progressive improvement over subsequent weeks, with the 
overall pattern of improvement approximating an exponential 
curve. Leucht et al. (2005) analyzed a large homogeneous data-
base of original patient data from 7 randomized, double-blind 
studies of the efficacy of amisulpride in patients with schizo-
phrenia spectrum disorders and found the same results. More 
improvement occurs in the first few days than in any later pe-
riod of equal duration (Leucht et al., 2005). Subsequent stud-
ies show that the onset occurs within the first day, contempo-
raneous with the blockade of dopamine receptors (Kapur et al., 
2005), and early nonimprovement (< 20% reduction in Brief Psy-
chiatric Rating Scale total score at 1 week) predicts nonresponse 
at 4 weeks (Correll et al., 2003).
Animal models play an important role in delineating the 
time course of antipsychotic action and related behavioral mech-
anisms (Abekawa et al., 2007; Sun et al., 2009). Among many an-
imal models of antipsychotic drugs, the phencyclidine (PCP)-in-
duced hyperlocomotion model seems especially useful for this 
purpose. First, the PCP model is sensitive to antipsychotic ac-
tion. Antipsychotic drugs, both typical (haloperidol), and atyp-
ical (clozapine, olanzapine, risperidone, aripiprazole) acutely 
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Clinical observations suggest that antipsychotic effect starts early and increases progressively over time. This time course of 
antipsychotic effect can be captured in a rat phencyclidine (PCP)-induced hyperlocomotion model, as repeated antipsychotic 
treatment progressively increases its inhibition of the repeated PCP-induced hyperlocomotion. Although the neural basis 
of acute antipsychotic action has been studied extensively, the system that mediates the potentiated effect of repeated anti-
psychotic treatment has not been elucidated. In the present study, we investigated the neuroanatomical basis of the potenti-
ated action of haloperidol (HAL) and clozapine (CLZ) treatment in the repeated PCP-induced hyperlocomotion. Once daily 
for five consecutive days, adult Sprague–Dawley male rats were first injected with HAL (0.05 mg/kg, sc), CLZ (10.0 mg/
kg, sc) or saline, followed by an injection of PCP (3.2 mg/kg, sc) or saline 30 min later, and motor activity was measured for 
90 min after the PCP injection. C-Fos immunoreactivity was assessed either after the acute (day 1) or repeated (day 5) drug 
tests. Behaviorally, repeated HAL or CLZ treatment progressively increased the inhibition of PCP-induced hyperlocomo-
tion throughout the five days of drug testing. Neuroanatomically, both acute and repeated treatment of HAL significantly in-
creased PCP-induced c-Fos expression in the nucleus accumbens shell (NAs) and the ventral tegmental area (VTA), but re-
duced it in the central amygdaloid nucleus (CeA). Acute and repeated CLZ treatment significantly increased PCP-induced 
c-Fos expression in the ventral part of lateral septal nucleus (LSv) and VTA, but reduced it in the medial prefrontal cortex 
(mPFC). More importantly, the effects of HAL and CLZ in these brain areas underwent a time-dependent reduction from 
day 1 to day 5. These findings suggest that repeated HAL achieves its potentiated inhibition of the PCP-induced hyperloco-
motion by acting on the NAs, CeA and VTA, while CLZ does so by acting on the mPFC, LSv and VTA.
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inhibit hyperlocomotion induced by PCP in rodents. Atypical 
drugs are less likely to cause extrapyramidal motor syndromes 
(EPS) and sustained prolactin elevation in comparison to typi-
cals. They also show a preferential inhibition on the PCP-in-
duced hyperlocomotion over the amphetamine-induced hy-
perlocomotion, whereas typicals do not seem to possess this 
preference. Thus, the PCP model is useful in distinguishing dif-
ferent classes of antipsychotics (Gleason and Shannon, 1997; 
Maurel-Remy et al., 1995; Millan et al., 1999). Second, repeated 
treatment of antipsychotic drugs progressively potentiates the 
inhibition of the PCP-induced hyperlocomotion across multiple 
drug testing sessions and prolonged this action within sessions 
(Sun et al., 2009), a time course of behavioral changes closely 
mimicking clinical effects. This property is not shared by antide-
pressants or anxiolytics (Sun et al., 2009). Therefore, it appears 
that the repeated PCP-induced hyperlocomotion model could 
serve as a valid model for the investigation of the neurobiolog-
ical and behavioral mechanisms of action of repeated antipsy-
chotic treatments.
c-Fos, a protein product of immediate-early gene c-fos has 
been used as a molecular biomarker for identifying neuronal ac-
tivation after a variety of behavioral, environmental, and phar-
macological stimuli. In the field of antipsychotic drugs, the abil-
ity of antipsychotic drugs to induce c-Fos expression in the 
forebrain regions has been closely linked to the action sites of 
antipsychotic activity and liability for producing extrapyramidal 
side effects (Robertson and Fibiger, 1992; Robertson et al., 1994). 
Acute administration of typical antipsychotic haloperidol (HAL) 
and atypical drug clozapine (CLZ) produces a different induc-
tion pattern of c-Fos expression in the forebrain, with acute HAL 
increasing Fos-positive neurons in the dorsolateral striatum 
(DLSt), nucleus accumbens shell and core (NAs and NAc), and 
lateral septal nucleus (LS) and acute CLZ producing such effects 
in the NAs, medial prefrontal cortex (mPFC) (Robertson and 
Fibiger, 1992; Robertson et al., 1994). Interestingly, psychotomi-
metic drugs of abuse such as PCP, amphetamine and MK-801 
also increase c-Fos expression in these brain areas (De Leoni-
bus et al., 2002; Habara et al., 2001; Rotllant et al., 2010; Sato et 
al., 1997; Zuo et al., 2009). Based on these observations, we pos-
tulated that by examining how antipsychotic treatment alters c-
Fos expression induced by PCP in the above mentioned brain 
regions at different time points of treatment, we may be able to 
identify the neuroanatomical bases of acute and potentiated inhi-
bition of HAL or CLZ treatment on PCP-induced hyperlocomo-
tion. In the present study, we used the c-Fos immunohistochem-
istry technique, together with a pharmacological tool (i.e. PCP) 
and behavioral observations (i.e. motor activity), to delineate the 
neural circuitries upon which HAL and CLZ act to achieve their 
acute and potentiated inhibitory effects on the PCP-induced hy-
perlocomotion. Because we considered the c-Fos effect in the 
context of antipsychotic activity (i.e. PCP-induced hyperlocomo-
tion), our approach ensured that the brain regions identified are 
behaviorally and neurochemically relevant to the specific action 
of HAL and CLZ.
2. Methods
2.1. Animals
Male Sprague–Dawley rats (220–250 g upon arrival, Charles 
River, Portage, MI) were housed in pairs in transparent polycar-
bonate cages (48.3 cm × 26.7 cm × 20.3 cm) under 12-hr light/
dark cycle (lights on from 6:30 am to 6:30 pm), with food and 
water available ad libitum. All animals were maintained in 
our colony with a controlled temperature (21 ± 1 °C) and a rel-
ative humidity of 55–60%. Animals were allowed at least one 
week of habituation to the animal facility before being used 
in experiments. All procedures were approved by the Insti-
tutional Animal Care and Use Committee at the University of 
Nebraska-Lincoln.
2.2. Drugs
The injection solution of haloperidol (HAL, 5.0 mg/ml ampoules, 
Sicor Pharmaceuticals, Inc., Irvine, CA) was obtained by mix-
ing drugs with sterile water. Phencyclidine hydrochloride (PCP, 
a gift from NIDA Drug Supply Program) and clozapine (CLZ, a 
gift from NIMH Drug Supply Program) were dissolved in 0.9% 
saline and 1.0% glacial acetic acid in distilled water, respectively. 
We chose haloperidol (0.05 mg/kg, sc) and clozapine (10.0 mg/
kg, sc) because they are clinically relevant doses based on the do-
pamine D2 receptor occupancy data (50–75% occupancy) (Kapur 
et al., 2003) and animal behavioral assessment of antipsychotic 
activity (Li et al., 2010, 2011). The dose for PCP was 3.2 mg/kg, 
which has been shown to induce a robust hyperlocomotion effect 
without causing severe stereotypy (Gleason and Shannon, 1997; 
Kalinichev et al., 2008; Sun et al., 2009). Haloperidol, clozapine 
and phencyclidine were administered subcutaneously.
2.3. Locomotor activity apparatus
Sixteen activity boxes were housed in a quiet room. The boxes 
were 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbon-
ate cages, which were similar to the home cages but were each 
equipped with a row of 6 photocell beams (7.8 cm between two 
adjacent photobeams) placed 3.2 cm above the floor of the cage. 
A computer detected the disruption of the photocell beams and 
recorded the number of beam breaks. All experiments were run 
during the light cycle from 9 am to 4 pm.
2.4. Experimental procedure
Thirty-two rats were randomly assigned to one of four groups 
(n = 8/group): vehicle (water) + vehicle (saline, SAL), vehi-
cle (water) + PCP, haloperidol (0.05 mg/kg) + PCP, clozapine 
(10.0 mg/kg) + PCP. After two days of habituation to the testing 
room and the testing boxes (30 min/day for 2 days), the drug 
test days started. On the first drug day, rats were brought to the 
testing room, and injected with vehicle (sterile water), haloperi-
dol (0.05 mg/kg), or clozapine (10.0 mg/kg). They were then im-
mediately placed in locomotor activity boxes for 30 min. At the 
end of the 30-min testing, rats were taken out and injected with 
either 0.9% saline (sc) or PCP (3.2 mg/kg, sc) and placed back 
in the boxes for another 90 min. Locomotor activity (number of 
photobeam breaks) was measured in 5 min intervals throughout 
the entire 120-min testing session. Half of rats from each group 
(4/group) were randomly selected and sacrificed immediately 
after the end of the 90-min testing for acute c-Fos assay. The re-
maining rats were repeatedly tested for another 4 days (a total 
of 5 tests) and sacrificed at the end of the last drug test day.
2.5. c-Fos immunohistochemistry
Immediately after the locomotor activity test, all rats were anes-
thetized with sodium pentobarbital (100.0 mg/kg) and then per-
fused with 4% paraformaldehyde. Brains were post-fixed and 
cryoprotected in 30% sucrose, and coronal sections (40 μm) were 
cut on a cryostat. Procedures for Fos immunohistochemistry fol-
lowed the protocol by Zhao and Li (2010). Briefly, sections were 
incubated with a rabbit polyclonal anti-c-Fos (Ab-5, PC38) anti-
body raised against residues 4–17 of human c-Fos (1:20000, Cal-
biochem, CA, USA) for 48 h at 4 °C. Sections were then incu-
bated with a biotinylated goat anti-rabbit secondary antibody 
(1:200, Vector Laboratories, Burlingame, CA, USA) in PBS con-
taining 1% NGS for 2 h at RT. They were processed with avi-
din–biotin horseradish peroxidase complex (1:200, Vectastain 
Elite ABC Kit, Vector Laboratories). The immunoreaction was 
visualized with peroxidase substrate (DAB Substrate Kit for 
Peroxidase, Vector Laboratories). After staining, sections were 
mounted on gelatin-coated slides, air-dried, dehydrated and 
coverslipped. As a control, the primary antibody was substi-
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tuted with normal rabbit serum. No corresponding nucleus or 
cytoplasm was immunostained in the control.
2.6. Fos-immunoreactive (Fos-I) cell counting
Photomicrographs were captured with a digital camera (INFIN-
ITY lite, Canada) equipped with an Olympus CX41RF micro-
scope (Japan) using × 10 objective lens. Fos-I cells characterized 
by clearly stained nuclei was counted bilaterally in one section 
with comparable anatomical levels across the treatment groups. 
The brain regions analyzed included the neural sites that were 
either implicated in the action of PCP and/or in the regulation 
of locomotor activity [e.g., the medial prefrontal cortex (mPFC), 
nucleus accumbens shell (NAs), nucleus accumbens core (NAc), 
dorsolateral striatum (DLSt), ventral part of lateral septal nu-
cleus (LSv), medial amygdaloid nucleus (MeA), central amyg-
daloid nucleus (CeA), and ventral tegmental area (VTA)]. The 
levels of brain slices were: Bregma 3.00 mm for mPFC, 1.92 mm 
for NAs, NAc and DLSt, 1.44 mm for LSv, − 2.92 mm for MeA 
and CeA, − 6.24 mm for VTA according to Paxinos and Watson 
(2007) (Figure 1). With the help of ImageJ software (developed 
at the US National Institutes of Health), cell counts were made 
within a 680 × 510 μm2 unit area of each interest region by an 
experimenter blind to the treatment condition. The images were 
thresholded and then analyzed. In a given area from distinct 
treatments, the images were thresholded to the same value by 
means of eliminating background and noise staining to ensure 
that the Fos-I cells were selected. The number of Fos-I nuclei of a 
given brain region from bilateral sites per rat was averaged. The 
values from four rats of each treatment group were averaged to 
obtain the final mean ± SEM.
2.7. Statistical analysis
Data for locomotor activity and the number of c-Fos immunore-
active cells were expressed as mean ± SEM and analyzed using 
a two-way analysis of variance (ANOVA) with treatment condi-
tions (VEH + VEH, VEH + PCP, HAL + PCP, CLZ + PCP) × test 
days (Day1, Day5) as between-subject factors, followed by post-
hoc Tukey tests to detect two-group difference. Locomotor ac-
tivity data from each daily test were analyzed using a factorial 
repeated measures ANOVA with the between-subjects factor 
being the treatment conditions (“Treatment”, e.g. vehicle, HAL 
or CLZ in combination with vehicle or PCP), and the within-
subjects factor being the 5-min time block (“Block”, e.g. block for 
90 min after PCP injection). A one-way ANOVA was used to test 
two-group difference where appropriate. The independent-sam-
ples T test was used to compare the acute and repeated effect 
of different treatment groups. A conventional two-tailed level 
of significance at the 0.05 level was required. Percent inhibition 
was calculated by subtracting the motor activity of the HAL/
CLZ + PCP group (T) from the motor activity of the VEH + PCP 
group (P), dividing by the motor activity of the VEH + PCP 
group, and multiplying by 100[(P – T)/P × 100].
3. Results
3.1. Repeated HAL or CLZ treatment potentiated the inhibition 
on the PCP-induced hyperlocomotion
On day 1, PCP significantly increased the mean motor activity 
during the 90-min testing period compared to the vehicle treat-
ment [Figure 2, F(3, 12) = 25.14, p < 0.001, post-hoc Tukey tests, 
p < 0.001 vs. vehicle]. This psychomotor stimulating effect was 
significantly attenuated by pretreatment with HAL (p = 0.008) 
and CLZ (p = 0.042). However, in comparison to the vehicle con-
trols, rats treated with HAL + PCP and CLZ + PCP still had sig-
nificantly higher motor activity (p = 0.004 versus HAL, p < 0.001 
versus CLZ), suggesting that the attenuation at the tested doses 
was not complete.
Across the 5 drug test days, repeated PCP treatment tended 
to progressively increase locomotor activity. In contrast, re-
peated HAL and CLZ pretreatment progressively enhanced 
their efficacy in inhibiting PCP-induced hyperlocomotion. 
A two-way repeated measures ANOVA revealed a main ef-
fect of “Treatment” [F(3, 12) = 90.31, p < 0.001], no main effect of 
“Day” [F(4, 48) = 1.53, p = 0.21], but a significant interaction be-
tween “Treatment” and “Day” [F(12, 48) = 1.89, p = 0.046]. The 
enhanced inhibition by repeated HAL and CLZ treatment was 
also revealed by the percent inhibition measure. According to 
this measure, HAL reduced PCP-induced hyperlocomotion by 
45% on day 1, but 77% on day 5. Similarly, CLZ reduced PCP-
induced hyperlocomotion by 29% on day 1, but up to 49% on 
day 5.
Figure 1. Schematic representation of the brain regions (black boxed 
areas) sampled for c-Fos immunoreactivity assessment. Distance from 
Bregma in the rostrocaudal planes is indicated. Drawings were modi-
fied from Paxinos and Watson (2007).
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3.2. Repeated HAL or CLZ treatment prolonged the time course 
of the inhibitory action on PCP-induced hyperlocomotion 
within session
Figure 3 shows the time course (measured in 5-min blocks for 
the 90-min period after PCP administration) of the effects of 
HAL or CLZ pretreatment on PCP-induced hyperlocomotion 
on the first and last days of drug testing. The two-way repeated 
measures ANOVA revealed a main effect of “Treatment” [F(3, 
12) = 25.14, p < 0.001 for day 1; F(3, 12) = 18.55, p < 0.001 for day 5], 
a main effect of “Time” [F(17, 204) = 4.63, p < 0.001 for day 1; F(17, 
204) = 8.52, p < 0.001 for day 5], and a significant interaction be-
tween “Treatment” and “Time” [F(51, 204) = 2.32, p < 0.001 for day 
1; F(51, 204) = 5.38, p < 0.001 for day 5]. With repeated treatment, 
HAL and CLZ prolonged their inhibition of PCP-induced hy-
perlocomotion. For example, on day 1, the significant inhibitory 
effect of HAL and CLZ started at the 15-min testing point after 
the PCP injection, and lasted for the remainder of the test ses-
sion (Figure 3a, all ps < 0.05 in comparison to the vehicle + PCP 
group). On day 5, the significant inhibition advanced to the 10-
min point (Figure 3b, all ps < 0.05).
3.3. Effects of acute HAL or CLZ treatment on PCP-induced c-
Fos immunoreactivity
A one-way ANOVA revealed a significant effect in the mPFC 
[F(3, 12) = 27.64, p < 0.001], NAs [F(3, 12) = 59.14, p < 0.001], NAc [F(3, 
12) = 14.03, p < 0.001], DLSt [F(3, 12) = 104.18, p < 0.001], LSv [F(3, 
12) = 24.14, p < 0.001], CeA [F(3, 12) = 77.04, p < 0.001], VTA [F(3, 
12) = 250.05, p < 0.001]. In comparison to the vehicle treatment, 
acute PCP treatment significantly increased the number of c-
Fos positive cells in the mPFC (p < 0.001), NAs (p < 0.001), NAc 
(p = 0.016), LSv (p = 0.021), CeA (p < 0.001) and VTA (p < 0.001), 
while having no detectable effect in the DLSt and MeA (Fig-
ure 4a). Acute HAL pretreatment further increased c-Fos expres-
sion induced by PCP in the NAs, NAc and VTA (all ps < 0.05), 
Figure 2. Effects of repeated haloperidol or clozapine treatment on 
PCP-induced hyperlocomotion over the five test days. Bars represent 
means ± SEM. * p < 0.05 versus VEH + VEH control; # p < 0.05 ver-
sus VEH + PCP group; &,$ p < 0.05 between Day 1, Day 2 and Day 4, 
Day 5.
Figure 3. Time course effect of haloperidol or clozapine treatment on PCP-induced hyperlocomotion on test day 1 (a) and day 5 (b). Locomotor ac-
tivity was measured over 18 5-min blocks and expressed as mean ± SEM for each group. # p < 0.05 versus VEH + PCP group.
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but reduced it in the CeA (p = 0.007) (Figure 4b). HAL itself 
also increased c-Fos expression in the DLSt where PCP had lit-
tle effect. Acute CLZ pretreatment significantly increased c-
Fos expression induced by PCP in the LSv (p = 0.002) and VTA 
(p < 0.001), but reduced it in the mPFC (p = 0.002) (Figure 4b). 
Table 1 summarizes the distinct effects of acute HAL or CLZ 
pretreatment on PCP-induced c-Fos increase. Both HAL and 
CLZ shared a common action in the VTA in enhancing the PCP-
induced c-Fos expression.
3.4. Effects of repeated HAL or CLZ treatment on PCP-induced 
c-Fos immunoreactivity
A one-way ANOVA revealed a significant effect in the mPFC 
[F(3, 12) = 26.62, p < 0.001], NAs [F(3, 12) = 42.28, p < 0.001], NAc 
[F(3, 12) = 35.76, p < 0.001], DLSt [F(3, 12) = 62.71, p < 0.001], LSv [F(3, 
12) = 51.64, p < 0.001], CeA [F(3, 12) = 94.28, p < 0.001], VTA [F(3, 
12) = 85.29, p < 0.001]. Similar to the acute effect, repeated PCP 
treatment significantly increased the number of c-Fos positive 
cells in the mPFC (p < 0.001), NAs (p = 0.036), LSv (p < 0.001), 
CeA (p < 0.001) and VTA (p = 0.023) (Figure 5a). Repeated HAL 
treatment resulted in an increase in PCP-induced c-Fos in the 
NAs, NAc and VTA (all ps < 0.001), while reduced it in CeA 
(p < 0.001) (Figure 5b). Repeated CLZ further increased PCP-
induced c-Fos in the LSv (p = 0.006), CeA (p < 0.001) and VTA 
(p = 0.001), while reduced it in the mPFC (p = 0.004) (Figure 5b). 
Table 2 summarizes the effects of repeated HAL or CLZ treat-
ment on PCP-induced c-Fos increase. The differences between 
the acute and repeated treatments of PCP, HAL and CLZ were 
apparent. For example, acute treatment of PCP increased Fos ex-
pression in the NAc, while repeated treatment had no effect. Re-
peated CLZ treatment further increased PCP-induced Fos ex-
pression in the CeA, while acute CLZ treatment had no effect ( 
Table 1 and Table 2).
3.5. Differences in c-Fos expression between acute and repeated 
drug treatment
In comparison to acute effects (day 1), repeated treatment (day 
5) resulted in a reduction in c-Fos immunoreactivity in most, but 
not all brain areas (Figure 6). The two-way ANOVA revealed a 
main effect of “Day” for mPFC [F(1, 24) = 12.35, p = 0.002], NAs 
[F(1, 24) = 36.53, p < 0.001], NAc [F(1, 24) = 8.05, p = 0.009], DLSt 
[F(1, 24) = 70.54, p < 0.001], LSv [F(1, 24) = 20.11, p < 0.001], CeA [F(1, 
24) = 91.41, p < 0.001], and VTA [F(1, 24) = 71.14, p < 0.001]. Spe-
cifically, the number of c-Fos positive cells was significantly re-
duced from day 1 to day 5 in the LSv with VEH + VEH (Fig-
ure 6a, p = 0.007); in the mPFC (p = 0.041), NAs (p = 0.006), NAc 
(p = 0.004), CeA (p = 0.006) and VTA (p = 0.003) with VEH + PCP 
(Figure 6b); in the mPFC (p = 0.015), NAs (p = 0.011), DLSt 
(p < 0.001), CeA (p < 0.001) and VTA (p = 0.001) with HAL + PCP 
(Figure 6c); and in the mPFC (p = 0.048), NAs (p = 0.003), DLSt 
(p = 0.02), LSv (p = 0.003), CeA (p = 0.007) and VTA (p = 0.016) 
with CLZ + PCP (Figure 6d).
Figure 4. Effects of acute treatment of PCP alone (a), and in combina-
tion with haloperidol or clozapine (b) on c-Fos expression in rat brain. 
Data were expressed as mean ± SEM. * p < 0.05 versus VEH + VEH 
control, # p < 0.05 versus VEH + PCP group.
Figure 5. Effects of repeated treatment of PCP alone (a), and in com-
bination with haloperidol or clozapine (b) on c-Fos expression 
in rat brain. Data were expressed as mean ± SEM. * p < 0.05 versus 
VEH + VEH control, # p < 0.05 versus VEH + PCP group.
Table 1. Effects of acute HAL or CLZ pretreatment on PCP-induced 
c-Fos expression in rat brain.
Treatment mPFC NAs NAc DLSt LSv MeA CeA    VTA
VEH + PCP Δ Δ Δ † Δ † Δ Δ
HAL + PCP ― ↑ ↑ ↑ ― ― ↓ ↑
CLZ + PCP ↓ ― ― ― ↑ ― ― ↑
Δ, increase; †, no significant effect relative to VEH + VEH control; 
↑, increase; ↓, decrease; ―, no significant effect relative to VEH + PCP 
treatment.
Table 2. Effects of repeated HAL or CLZ pretreatment on PCP- 
induced c-Fos expression in rat brain.
Treatment mPFC NAs NAc DLSt LSv MeA CeA VTA
VEH + PCP Δ Δ † † Δ † Δ Δ
HAL + PCP ― ↑ ↑ ↑ ― ― ↓ ↑
CLZ + PCP ↓ ― ― ― ↑ ― ↑ ↑
Δ, increase; †, no significant effect relative to VEH + VEH control; 
↑, increase; ↓, decrease; ―, no significant effect relative to VEH + PCP 
treatment.
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3.6. c-Fos identification of brain regions involved in the potenti-
ation of inhibitory effect of repeated HAL or CLZ treatment on 
PCP-induced hyperlocomotion
Based on the changes of c-Fos expression, a brain region had 
to meet the following three criteria in order to be considered 
as part of the neural circuit(s) by which HAL and CLZ act to 
achieve their potentiated inhibitory effect on the PCP-induced 
hyperlocomotion. First, it should show altered c-Fos expression 
in response to both acute and repeated treatment of PCP. Sec-
ond, it should show altered PCP-induced c-Fos expression in re-
sponse to acute and repeated treatment of HAL or CLZ. Third, it 
should show a change in c-Fos expression from day 1 to day 5. 
Based on these criteria, three regions including NAs, CeA and 
VTA could be classified as part of the HAL neural circuit, and 
three regions including mPFC, LSv and VTA as part of the CLZ 
neural circuit. Table 3 summarizes the results of how these re-
gions met these criteria.
4. Discussion
The present study differs from most other studies in the litera-
ture in which it examined the repeated effects of HAL and CLZ 
treatment on the neuronal activities (as indexed by the c-Fos ex-
pression) in a validated animal model of antipsychotic activ-
ity (i.e. the PCP hyperlocomotion model). Most studies in this 
field only focus on the acute effects of antipsychotic treatment 
in normal animals (Robertson and Fibiger, 1992; Robertson et al., 
1994). The present study filled these knowledge gaps. Behavior-
ally, we replicated our previous finding that repeated antipsy-
chotic treatment progressively potentiates the inhibition of the 
PCP-induced hyperlocomotion, a behavioral pattern closely re-
sembling the characteristics of time course of antipsychotic ac-
tions in the clinic (Sun et al., 2009). Furthermore, we delineated 
possible neuronal mechanisms of the time course of antipsy-
chotic action. We showed that both acute and repeated treat-
ment of HAL significantly increased PCP-induced c-Fos ex-
pression in the NAs and VTA, while reduced it in the CeA. In 
contrast, CLZ treatment enhanced PCP-induced c-Fos in the LSv 
and VTA, but reduced it in the mPFC. More importantly, the ef-
fects of HAL and CLZ in these brain areas underwent a time-de-
pendent reduction from day 1 to day 5, consistent with their ef-
fects at the behavioral levels. These findings indicate that these 
brain areas are the likely sites upon which HAL or CLZ act on to 
inhibit the psychomotor activation effect of PCP. Thus, we sug-
gest that HAL may achieve its potentiated inhibitory effect on 
PCP-induced hyperlocomotion via acting on the NAs, CeA and 
VTA, while CLZ does so via the mPFC, LSv and VTA.
Phencyclidine (PCP) has been extensively used to mimic 
the positive and negative symptoms of schizophrenia in vari-
ous animal models (Javitt and Zukin, 1991; Mouri et al., 2007; 
Sams-Dodd, 1998). Among many behavioral tasks, the hyperlo-
comotion model is commonly used as a screening tool for the 
Figure 6. Effects of acute and repeated treatment of haloperidol or clozapine on PCP-induced c-Fos expression in rat brain. c-Fos expression was 
assessed in four distinct groups: VEH + VEH (a), VEH + PCP (b), HAL + PCP (c) and CLZ + PCP (d). Data were expressed as mean ± SEM. * 
p < 0.05 between Day 1 and Day 5.
Table 3. Brain regions considered to be part of the neural circuit 
through which HAL and CLZ act to achieve their potentiated inhibi-
tory effect on PCP-induced hyperlocomotion using neuronal marker 
of c-Fos.
Brain regions mPFC NAs LSv CeA VTA
Criterion 1 (PCP effect) Δ Δ Δ Δ Δ
Criterion 2 (response to HAL)  ↑  ↓ ↑
Criterion 2 (response to CLZ) ↓  ↑  ↑
Criterion 3 (change from acute  + + + + + 
    to repeated treatment)
Δ, increase relative to VEH + VEH control; ↑, increase; ↓, decrease 
relative to VEH + PCP treatment; +, change from acute to repeated 
treatment.
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detection of antipsychotic activity. When given acutely, many 
antipsychotics inhibit the hyperlocomotor activity induced by 
acute administrations of PCP (Gleason and Shannon, 1997; Mil-
lan et al., 1999). However, this acute effect is limited in its abil-
ity to capture the intrinsic antipsychotic efficacy of a drug and 
mimic the time course of antipsychotic treatment in the clinic 
(Agid et al., 2003; Leucht et al., 2005). This is because that the in-
hibition of PCP induced hyperlocomotion is not exclusively the 
property of antipsychotics. Drugs that antagonize 5-HT2A recep-
tors but are not antipsychotics such as LY53857, ritanserin, ket-
anserin, fananserin, and MDL 100,907 also block PCP-induced 
hyperlocomotion (Gleason and Shannon, 1997; Millan et al., 
1999). Therefore, the neural basis of PCP effect or antipsychotic 
effect identified through c-Fos immunocytochemistry based on 
the acute treatment model is questionable. On the other hand, 
repeated administration of PCP induces an array of behavioral 
and neurochemical changes that mimic those found in schizo-
phrenia better than acute administration of PCP (Jentsch and 
Roth, 1999). More importantly, repeated antipsychotic treat-
ment, but not anxiolytic (e.g. chlordiazepoxide) or antidepres-
sant treatment (e.g. fluoxetine and citalopram) progressively 
potentiates the inhibition of the PCP-induced hyperlocomotion 
across sessions and prolongs this action within sessions (Red-
mond et al., 1999; Sun et al., 2009). Because clinical antipsychotic 
treatment also requires medications be taken for a prolonged 
period of time, and the overall antipsychotic effects show an 
exponential curve and reach their full therapeutic benefit in 
2–3 weeks (Agid et al., 2006), we postulated that the repeated 
PCP-induced hyperlocomotion model based on a repeated an-
tipsychotic treatment regimen could serve as a valid model to 
investigate the neurochemical and neural mechanisms of action 
of antipsychotic drugs. This was the rationale upon which the 
current c-Fos study was based on, and we believe that the brain 
regions identified through this approach are behaviorally and 
neurochemically relevant to the specific action of HAL and CLZ.
Previous work indicates that PCP treatment induces c-Fos 
expression in the brain in a region-specific manner. Acute PCP 
treatment is shown to increase c-Fos protein and mRNA expres-
sion in the mPFC, piriform, cingulate and insular cortices, nu-
cleus accumbens (NA) and lateral septal nucleus (LS) (Gotoh et 
al., 2002; Habara et al., 2001; Kargieman et al., 2007; Näkki et al., 
1996; Sato et al., 1997; Sugita et al., 1996). In the present study, we 
also found increased c-Fos expression in the mPFC, NA and LS. 
In addition, we found a c-Fos increase in the VTA and CeA, sug-
gesting that the VTA and CeA, together with the mPFC, NA and 
LS, are parts of a neural network upon which PCP acts to achieve 
its behavioral effects. Indeed, PCP microinfused into the mPFC 
was shown to cause a hyperlocomotion, and this motor-stimu-
lating effect was attenuated by pharmacological lesions of the 
mPFC (Jentsch et al., 1998). Direct infusion of PCP into the NA 
also increased locomotor activity (McCullough and Salamone, 
1992). Systemic and site-directed injection of PCP to the NA pro-
duced an increase in extracellular dopamine levels in the NA 
(Carboni et al., 1989; Hernandez et al., 1988; McCullough and 
Salamone, 1992; Millan et al., 1999). Depletion of dopamine by 
microinjection of 6-hydroxydopamine (6-OHDA) into the NA or 
VTA inhibited the PCP-induced hyperlocomotion (French, 1986; 
Steinpreis and Salamone, 1993). Finally, systemic administration 
of HAL significantly reduced the hyperlocomotion induced by 
intra-accumbens injection of PCP (McCullough and Salamone, 
1992). All these findings support the hypothesis that PCP affects 
multiple brain areas including the mPFC, NA (shell and core), 
CeA and VTA to achieve its psychotomimetic effect.
If this hypothesis is correct, we would also expect that pre-
treatment of HAL or CLZ should alter PCP-induced c-Fos ex-
pression in these brain areas. Indeed, we found that both acute 
and repeated pretreatment with HAL significantly increased 
PCP-induced c-Fos expression in the NAs and VTA, while re-
duced it in CeA. Similarly, CLZ pretreatment further increased 
PCP-induced c-Fos in the LSv and VTA, while reduced it in 
the mPFC (Figs. 4b, 5b). Interestingly, the c-Fos expression in 
these areas underwent a time-dependent reduction from day 1 
to day 5, consistent with the observed HAL and CLZ potenti-
ated inhibition of PCP-induced hyperlocomotion from day 1 to 
day 5. This pattern of change in c-Fos expression over the re-
peated treatment period has been reported before in the studies 
of drugs of abuse (Hope et al., 1992; Persico et al., 1993; Rosen 
et al., 1994; Salminen et al., 1999), antipsychotic drugs (Atkins 
et al., 1999; Coppens et al., 1995; Hiroi and Graybiel, 1996; Se-
bens et al., 1995) and chronic stress (Melia et al., 1994; Stamp 
and Herbert, 1999; Umemoto et al., 1997). The exact mechanism 
responsible for this time-dependent c-Fos reduction is still not 
clear. It may be an intrinsic neuroadaptation of the brain in re-
sponse to various stimuli.
The mechanism of action of PCP is complex (Jentsch and 
Roth, 1999). Besides blocking NMDA receptor channels, PCP 
can enhance serotonergic, dopaminergic and glutamatergic neu-
rotransmission in the NA and PFC (Abekawa et al., 2007; Mau-
rel-Remy et al., 1995; Millan et al., 1999). Because typical anti-
psychotics with preferential action on D2 receptors such as 
HAL, and atypicals drugs with mixed D2-like/5-HT2A antago-
nism such as CLZ and olanzapine all inhibit the PCP-induced 
hyperlocomotion (Gleason and Shannon, 1997; Maurel-Remy et 
al., 1995; Millan et al., 1999), and other 5-HT2A antagonists such 
as LY53857, ritanserin, ketanserin, fananserin, and MDL 100, 
907, but not 5-HT1A or 5-HT3 antagonists such as WAY 100,635 
and zatosetron, also reduce the PCP-induced hyperlocomotion 
(Gleason and Shannon, 1997; Millan et al., 1999), it has been sug-
gested that the inhibition of PCP-induced hyperlocomotion is 
primarily due to multiple actions of antipsychotics on dopamine 
D2 and 5-HT2A receptors (Gleason and Shannon, 1997; Maurel-
Remy et al., 1995; Millan et al., 1999). This hypothesis is further 
supported by the findings that depletion of 5-HT in the NA by 
parachloroamphetamine abolishes PCP-induced hyperlocomo-
tion (Millan et al., 1999); M100907, a selective 5-HT2A receptor 
antagonist, attenuated PCP-induced c-Fos in the NA, insular 
cortex and piriform cortex (Habara et al., 2001); and blockade of 
dopamine D2 receptors reduced the extracellular dopamine lev-
els in the NA (McCullough and Salamone, 1992). So for HAL, 
we suggest that its potentiated inhibition of the PCP-induced 
hyperlocomotion is due to its D2 antagonism in the NAs, CeA 
or VTA which leads to a reduction of PCP-induced dopamine 
increase. Repeated administration of CLZ causes a down-regu-
lation of 5-HT2A receptors in the PFC (Doat-Meyerhoefer et al., 
2005), microinjection of PCP into the prefrontal cortex elicits hy-
perlocomotion (Abekawa et al., 2007), we speculate that CLZ 
may enhance its inhibition of the PCP-induced hyperlocomotion 
by down-regulating 5-HT2A receptors and concomitantly de-
creasing PCP-induced glutamate, dopamine and 5-HT increases 
in the mPFC, LSv and VTA (Abekawa et al., 2007).
In conclusion, using the Fos immunoreactivity as markers of 
neuronal activation, we showed that typical antipsychotic HAL 
appears to achieve its potentiated inhibitory effect on the PCP-
induced hyperlocomotion primarily via acting on the NAs, CeA 
and VTA, while CLZ works primarily via the mPFC, LSv and 
VTA. It should be pointed out that while c-Fos is an important 
step in illuminating the differences in neuronal actions between 
haloperidol and clozapine in this task, these data should be re-
garded as one piece of evidence toward delineating the neu-
ral basis of these drug effects. Thus, other indices such as neu-
rotransmitter release, receptor density changes should be used 
to validate the current findings in future work.
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